Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Amidino derivatives and their use as thrombin inhibitors

a technology of amidino derivatives and inhibitors, which is applied in the direction of phosphorous compound active ingredients, drug compositions, group 5/15 element organic compounds, etc., can solve problems such as thromboembolic diseases

Inactive Publication Date: 2001-04-24
ASTRAZENECA AB
View PDF60 Cites 26 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The compounds of the invention have the advantage that they may be more efficacious, be less toxic, be longer acting, have a broader range of activity, be more potent, produce fewer side effects, be more easily absorbed than, or that they may have other useful pharmacological properties over, compounds known in the prior art.

Problems solved by technology

It is known that hypercoagulability may lead to thrombo-embolic diseases.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Amidino derivatives and their use as thrombin inhibitors
  • Amidino derivatives and their use as thrombin inhibitors
  • Amidino derivatives and their use as thrombin inhibitors

Examples

Experimental program
Comparison scheme
Effect test

example 1

N-{3-[2-(4-Aminoiminomethylphenyl)ethoxy]phenyl}benzenesulfonamide.times.HCl

(i) t-Butyloxycarbonylamino-3-hydroxybenzene

Amino-3-hydroxybenzene (5.46 g; 50 mmol) was dissolved in THF (50 mL) and di-t-butyl dicarbonate (12.0 g; 55 mmol) was added at room temperature. The solution was heated for 2 hours at 60.degree. C., the solvent was evaporated and the residue was dissolved in EtOAc (150 mL). The EtOAc-phase was washed with 2.times.20 mL of 1M KHSO.sub.4, 1.times.20 mL water, 1.times.20 mL brine and then dried (MgSO.sub.4). The solvent was evaporated to give 11.74 g of a colourless oil which was crystallised from CH.sub.2 Cl.sub.2 :MeOH:light petroleum to give 9.1 g (87%) of the sub-title compound as white crystals.

.sup.1 H-NMR (400 MHz; CDCl.sub.3): .delta.7.10-7.15 (bs, 1H), 7.11 (t, 1H), 6.72 (dd, 1H), 6.53 (dd, 1H), 6.50 (bs, 1H), 5.57 (apparent bs, 1H), 1.52 (s, 9H) .sup.13 C-NMR (100 MHz; CDCl.sub.3): .delta.156.4, 152.8, 139.4, 129.9, 110.7, 110.2, 105.9, 80.8, 28.3

(ii) t-But...

example 2

Benzenesulfoniacid-{3-[2-(4-aminoiminomethylphenyl)ethoxy]-5-methyl}-phenyl ester.times.HCl

(i) Benzenesulfonic acid-(3-hydroxy-5-methyl)phenyl ester

Benzenesulfonyl chloride (6.36 g; 36 mmol) was added to a well stirred mixture of 3,5-dihydroxytoluene.times.H.sub.2 O (4.26 g; 30 mmol), saturated aqueous NaHCO.sub.3 (70 mL) and Et.sub.2 O (50 mL) and the mixture was stirred at room temperature for 19 hours. Et.sub.2 O (50 mL) was added and the organic layer was separated, collected and evaporated to give 7.05 g of a powder. The crude material was recrystallized from EtOAc:heptane (30 mL:300 mL) to give 4.36 g (55%) of the sub-title compound.

FAB-MS 265 (M+1).sup.+

.sup.1 H-NMR (400 MHz; CDCl.sub.3): .delta.7.86 (d, 2H), 7.67 (tt, 1H), 7.53 (t, 2H), 6.54 (bs, 1H), 6.38 (bs, 1H), 6.31 (t, 1H), 5.02 (s, 1H, OH), 2.21 (s, 3H)

(ii) Benzenesulfonic acid-{3-[2-(4-cyanophenyl)ethoxy]-5-methyl}phenyl ester

Diethylazodicarboxylate (1.74 g; 10 mmol) was added, over 5 minutes, to a stirred solution o...

example 3

N-{3-[2-(4-Aminoiminomethylphenyl)ethoxyl]phenyl}-2-chlorobenzenesulfonamide.times.HOAc

(i) Nitro-3-[2-(4-cyanophenyl)ethoxy]benzene

Triphenylphosphine (11.3 g; 43.1 mmol) and diethylazodicarboxylate (7.5 g; 43 mmol) were dissolved in THF (250 mL) under nitrogen at 0.degree. C. After 5 minutes, 3-nitrophenol (5.00 g; 35.9 mmol) and 2-(4-cyanophenyl)ethanol (6.3 g; 43 mmol) were added. The cooling bath was removed and the mixture stirred for 2 days at room temperature. A new batch was prepared as above and the two were combined before work-up. Water was added and the THF was evaporated. The mixture was extracted with EtOAc, and the organic phase was washed with aqueous 0.2M NaOH and brine, dried (Na.sub.2 SO.sub.4) and the solvent removed in vacuo. Purification by flash chromatography (SiO.sub.2 ; toluene) and recrystallization from CH.sub.2 Cl.sub.2 :EtOH afforded 3.07 g (32%) of the sub-title compound.

.sup.1 H NMR (500 MHz; CDCl.sub.3): .delta.7.82 (dd, 1H), 7.61-7.71 (several peaks,...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
temperatureaaaaaaaaaa
pHaaaaaaaaaa
ionic strengthaaaaaaaaaa
Login to View More

Abstract

There is provided compounds of formula I,wherein R1, R2, R3, Y, n and B have meanings given in the description which are useful as competitive inhibitors of trypsin-like proteases, such as thrombin, and in particular in the treatment of conditions where inhibition of thrombin is required (e.g. thrombosis) or as anticoagulants.

Description

This invention relates to novel pharmaceutically useful compounds, in particular competitive inhibitors of trypsin-like serine proteases, especially thrombin, their use as medicaments, pharmaceutical compositions containing them and synthetic routes to their production.Blood coagulation is the key process involved in both haemostasis (i.e. the prevention of blood loss from a damaged vessel) and thrombosis (i.e. the formation of a blood clot in a blood vessel, sometimes leading to vessel obstruction).Coagulation is the result of a complex series of enzymatic reactions. One of the ultimate steps in this series of reactions is the conversion of the proenzyme prothrombin to the active enzyme thrombin.Thrombin is known to play a central role in coagulation. It activates platelets, leading to platelet aggregation, converts fibrinogen into fibrin monomers, which polymerise spontaneously into fibrin polymers, and activates factor XIII, which in turn crosslinks the polymers to form insoluble...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(United States)
IPC IPC(8): C07C311/21C07C323/60C07C323/00C07C311/29C07C309/00C07C311/00C07C309/73C07D233/84C07D261/00C07D233/00C07D333/00C07D261/16C07D333/34C07F9/53C07F9/00A61K31/155A61K31/18A61K31/216A61K31/255A61K31/27A61K31/275A61K31/381A61K31/4164A61K31/42A61P7/02C07C309/71C07C311/13C07D233/56C07D261/14
CPCC07C309/73C07C311/21C07C311/29C07F9/5304C07D233/84C07D261/16C07D333/34C07C323/60A61P7/02C07C309/71A61K31/18
Inventor ANTONSSON, THOMAS
Owner ASTRAZENECA AB
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com